12:00 AM
 | 
Oct 05, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Casopitant regulatory update

GlaxoSmithKline said it is withdrawing all regulatory applications for casopitant, including an NDA and MAA, for the treatment of chemotherapy-induced...

Read the full 76 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >